^
    Back
    Association details:
    Biomarker:PTEN deletion + BCL2 translocation
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor) +
    Aliqopa (copanlisib) (PIK3CA inhibitor, PI3Kδ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2018
    Title:

    Targeted Inhibition of PI3K a/d Is Synergistic with BCL-2 Blockade in Genetically Defined Subtypes of DLBCL

    Published date:
    11/01/2018
    Excerpt:
    We next assessed copanlisib and venetoclax activity in an in vivo xenograft model using a DLBCL cell line with PTENdel and BCL2 translocation (LY1)…Most notably, we found that the combination of copanlisib and venetoclax delayed tumor growth significantly longer than single-agent venetoclax (p<0.0001).
    DOI:
    https://doi.org/10.1182/blood-2018-99-113647